Engineered graphene quantum dot nanocomposite triggers α-synuclein defibrillation: Therapeutics against Parkinson's disease

IF 4.7 4区 医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Poonkuzhali Kaliyaperumal , Seenivasagan Renganathan , Karthika Arumugam , Bukola Rhoda Aremu
{"title":"Engineered graphene quantum dot nanocomposite triggers α-synuclein defibrillation: Therapeutics against Parkinson's disease","authors":"Poonkuzhali Kaliyaperumal ,&nbsp;Seenivasagan Renganathan ,&nbsp;Karthika Arumugam ,&nbsp;Bukola Rhoda Aremu","doi":"10.1016/j.nano.2022.102608","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Emerging clinically required α-synuclein (α-syn) inhibitor which acts as a neuroprotective<span><span> nanocomposite </span>drug is in increased demand as a patient-safe </span></span>central nervous system<span> therapeutic. This inhibitor is intended to chemically engineer graphene quantum dot (GQD) with blue luminescence, and stands to be a potential cure for </span></span>Parkinson's disease. It has been theorized that α-syn aggregation is a critical step in the development of Parkinson's. Hence narrow the target by α-syn inhibition, through chemically synthesize methyl </span><em>N</em>-allyl <em>N</em><span>-benzoylmethioninate (MABM) and functionally engineer the surface of GQD to target the brain delivery on C57BL/6 mice. Spectroscopic and simulation studies confirm defibrillation<span> through the interaction between N-terminal amino acids<span> and MABM-GQD nanoparticles<span>, which makes nontoxic α-syn. Therefore, this drug's ability to cross the blood-brain barrier in vitro functionally prevents neuronal loss in neuroblastoma cells. Thus, in vivo cerebral blood flow analysis using magnetic resonance imaging illustrates, how this nanocomposite can possibly treat Parkinson's.</span></span></span></span></p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":"47 ","pages":"Article 102608"},"PeriodicalIF":4.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine: Nanotechnology, Biology and Medicine","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963422000946","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Emerging clinically required α-synuclein (α-syn) inhibitor which acts as a neuroprotective nanocomposite drug is in increased demand as a patient-safe central nervous system therapeutic. This inhibitor is intended to chemically engineer graphene quantum dot (GQD) with blue luminescence, and stands to be a potential cure for Parkinson's disease. It has been theorized that α-syn aggregation is a critical step in the development of Parkinson's. Hence narrow the target by α-syn inhibition, through chemically synthesize methyl N-allyl N-benzoylmethioninate (MABM) and functionally engineer the surface of GQD to target the brain delivery on C57BL/6 mice. Spectroscopic and simulation studies confirm defibrillation through the interaction between N-terminal amino acids and MABM-GQD nanoparticles, which makes nontoxic α-syn. Therefore, this drug's ability to cross the blood-brain barrier in vitro functionally prevents neuronal loss in neuroblastoma cells. Thus, in vivo cerebral blood flow analysis using magnetic resonance imaging illustrates, how this nanocomposite can possibly treat Parkinson's.

Abstract Image

工程石墨烯量子点纳米复合材料触发α-突触核蛋白除颤:治疗帕金森病
α-突触核蛋白(α-syn)抑制剂作为一种神经保护纳米复合药物,作为一种对患者安全的中枢神经系统治疗药物,其临床需求日益增加。这种抑制剂旨在化学工程石墨烯量子点(GQD)发出蓝色发光,有望成为治疗帕金森病的潜在方法。理论上α-syn聚集是帕金森病发展的关键步骤。因此,通过α-syn抑制来缩小靶点,通过化学合成甲基n -烯丙基n -苯甲酰甲硫氨酸(MABM),并对GQD表面进行功能工程修饰,靶向C57BL/6小鼠脑内给药。光谱和模拟研究证实了n端氨基酸与MABM-GQD纳米粒子的相互作用,产生无毒的α-syn。因此,这种药物在体外通过血脑屏障的能力在功能上防止了神经母细胞瘤细胞的神经元损失。因此,使用磁共振成像的体内脑血流分析说明了这种纳米复合材料如何可能治疗帕金森病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.10
自引率
3.60%
发文量
104
审稿时长
4.6 months
期刊介绍: Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信